

Supplement Table S1: Background data for Ingenio El Angel, El Salvador.

Participation data for Ingenio El Angel, El Salvador cohort Year 2 (2015-2016).

	Number of Cutters	
Baseline measurements		334
Number of serum creatinine measurements during harvest year 2, (N)	0	75
	1	28
	2	79
	3	152

 Descriptive data concerning Ingenio El Angel, El Salvador cohort Year 2 (2015-2016) - Subjects with ≥ 1 measurements during harvest.

	N	259
Sex, N women (%)		46 (18%)
Age (years), median (IQR)		32 (24–43)
Baseline eGFR (ml/min/1.73 m ²), median (IQR)		90 (67–108)

Supplement Table S2: Results from women in El Salvador, year 2

Kidney injury and risk factors among female sugarcane cutters.

El Salvador		
Worker follow-up occasions		
	Total	IKI
Age		
18–30	42	0
31–40	49	2 (4%)
41–50	12	0
>50	17	5 (29%)
Baseline eGFR		
>90	54	0
90–60	59	5 (8%)
45–60	7	2 (29%)
<45	0	-
Baseline CRP (mg/L)		
<3	77	3 (4%)
3–10	38	4 (11%)
10–20	5	0
>20	0	-
Follow-up CRP (mg/L)		
<3	62	1 (2%)
3–10	48	4 (8%)
10–20	6	0
>20	4	2 (50%)
Baseline Mg (mmol/L)		
≥0.7	112	5 (4%)
<0.7	8	2 (25%)
Baseline K		
≥3.5	118	7 (6%)
<3.5	2	0
Follow-up K		
≥3.5	109	5 (5%)
<3.5	11	2 (2%)

Kidney injury and continuous biochemical parameters in female sugarcane cutters.

		Baseline	Median (IQR) Non IKI Day	IKI Day
Worker-days	N	46	113	7
CRP	mg/dL	1.6 (0.9–4.0)	2.8 (1.5–5.7)	6.0 (3.8–28)
Uric acid	mmol/L	279 (215–332)	265 (219–308)	370 (388–434)
CPK	μkat/L	1.6 (1.2–1.9)	2.2 (1.8–2.8)	3.1 (2.1–5.3)

Supplement Table S3: Multivariate regression analyses

Nicaragua (Adelante Cohort)					
Worker-harvests					
Total	IKI	Incidence Ratio (IR) (95% CI)	IR Adjusted for Job and Year (95% CI)	IR Adjusted for NSAID, CRP and Fever (95% CI)	IR Adjusted for Sugary Drink, Water and Boli Intake (95% CI)
Age (years)					
18-30	320	32 (10%)	ref	Ref	
31-40	155	16 (10%)	1.0 (0.6–1.9)	0.9 (0.5–1.7)	
41-50	43	5 (12%)	1.2 (0.5–3.0)	1.0 (0.4–2.7)	
>50	14	0 (0%)	NA	NA	
eGFR, baseline (mL/min/1.73m ²)					
>90	358	29 (8%)	Ref	Ref	
90-60	163	23 (14%)	1.7 (1.0–3.0)	1.5 (0.9–2.6)	
45-60	10	1 (10%)	1.2 (0.2–9.1)	1.0 (0.1–7.7)	
<45	1	0 (0%)	NA	NA	
CRP, baseline (mg/L)					
<3	423	40 (9%)	Ref	Ref	
3-10	85	12 (14%)	1.5 (0.8–2.8)	1.5 (0.8–2.8)	
10-20	12	0 (0%)	NA	NA	
>20	12	1 (8%)	0.9 (0.1–6.4)	1.1 (0.1–7.9)	
CRP, follow-up (mg/L)					
<3	340	10 (3%)	Ref	Ref	Ref
3-10	142	14 (10%)	3.4 (1.5–7.5)	2.8 (1.2–6.4)	3.5 (1.5–8.2)
10-20	24	9 (38%)	13 (5–31)	11 (4.5–28)	12 (5–31)
>20	26	20 (77%)	26 (12–56)	21 (10–45)	26 (12–60)
NSAID use at least once per week†					
No	444	37 (8%)	Ref	Ref	Ref
Yes	88	16 (18%)	2.2 (1.2–3.9)	1.8 (1.0–3.3)	2.0 (1.1–3.7)
Incident fever in past week(s) ††					
No	463	40 (9%)	Ref	Ref	Ref
Yes	43	11 (26%)	3.0 (1.5–5.8)	2.7 (1.4–5.3)	1.1 (0.5–2.2)

Sugary drink intake (L)					
<0.2	64	2 (3%)	Ref	Ref	Ref
0.2–1	312	30 (10%)	3.1 (0.7–13)	3.3 (0.8–14)	3.0 (0.7–12)
>1	155	21 (14%)	4.3 (1.0–18)	4.6 (1.1–20)	4.0 (0.9–17)
Morning boli intake (N of 300 mL electrolyte sachets)					
0	125	18 (14%)	Ref	Ref	Ref
0–3	214	23 (11%)	0.7 (0.4–1.4)	0.8 (0.4–1.4)	0.8 (0.4–1.6)
≥3	180	12 (7%)	0.4 (0.2–0.9)	0.5 (0.2–1.1)	0.5 (0.2–1.1)
Morning water intake (L)					
0–2	76	12 (16%)	Ref	Ref	Ref
2–5	209	18 (9%)	0.5 (0.3–1.1)	0.6 (0.3–1.2)	0.7 (0.3–1.5)
>5	246	23 (9%)	0.6 (0.3–1.2)	0.8 (0.4–1.7)	0.9 (0.4–2.0)

Job: seed cutter and burned cane cutter. Year: 2017–2018 and 2018–2019. NSAID: Non-steroidal anti-inflammatory drugs. CRP: C-reactive protein.